HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A single early activation of invariant NK T cells confers long-term protection against collagen-induced arthritis in a ligand-specific manner.

Abstract
The glycosphingolipid alpha-galactosylceramide (alpha-GalCer) has been shown to be a potent activator of invariant NKT (iNKT) cells, rapidly inducing large amounts of both Th1 and Th2 cytokines upon injection in mice. The C-glycoside analog of alpha-GalCer (alpha-C-GalCer), by contrast, results in an enhanced Th1-type response upon activation of iNKT cells. We administered a single dose of these Ags to DBA/1 mice during the early induction phase of collagen-induced arthritis and demonstrated therapeutic efficacy of alpha-GalCer when administered early rather than late during the disease. Surprisingly, the Th1-polarizing analog alpha-C-GalCer also conferred protection. Furthermore, a biphasic role of IFN-gamma in the effect of iNKT cell stimulation was observed. Whereas in vivo neutralization of IFN-gamma release induced by either alpha-GalCer or alpha-C-GalCer early during the course of disease resulted in partial improvement of clinical arthritis symptoms, blockade of IFN-gamma release later on resulted in a more rapid onset of arthritis. Although no phenotypic changes in conventional T cells, macrophages, or APCs could be detected, important functional differences in T cell cytokine production in serum were observed upon polyclonal T cell activation, 2 wk after onset of arthritis. Whereas alpha-GalCer-treated mice produced significantly higher amounts of IL-10 upon systemic anti-CD3 stimulation compared with PBS controls, T cells from alpha-C-GalCer-treated mice, by contrast, produced substantially lower levels of cytokines, suggesting the involvement of different protective mechanisms. In conclusion, these findings suggest long-term, ligand-specific, time-dependent, and partially IFN-gamma-dependent immunomodulatory effects of iNKT cells in collagen-induced arthritis.
AuthorsKen Coppieters, Katrien Van Beneden, Peggy Jacques, Pieter Dewint, Ann Vervloet, Bert Vander Cruyssen, Serge Van Calenbergh, Guangwu Chen, Richard W Franck, Gust Verbruggen, Dieter Deforce, Patrick Matthys, Moriya Tsuji, Pieter Rottiers, Dirk Elewaut
JournalJournal of immunology (Baltimore, Md. : 1950) (J Immunol) Vol. 179 Issue 4 Pg. 2300-9 (Aug 15 2007) ISSN: 0022-1767 [Print] United States
PMID17675491 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • CD3 Complex
  • Galactosylceramides
  • Immunologic Factors
  • Ligands
  • alpha-galactosylceramide
  • Interleukin-10
  • Interferon-gamma
Topics
  • Animals
  • Antigen-Presenting Cells (immunology, pathology)
  • Arthritis, Experimental (immunology, pathology, prevention & control)
  • CD3 Complex (immunology)
  • Galactosylceramides (administration & dosage)
  • Immunologic Factors (administration & dosage)
  • Interferon-gamma (immunology)
  • Interleukin-10 (immunology)
  • Killer Cells, Natural (immunology, pathology)
  • Ligands
  • Lymphocyte Activation (drug effects)
  • Macrophages (immunology, pathology)
  • Male
  • Mice
  • Mice, Inbred DBA
  • Th1 Cells (immunology, pathology)
  • Th2 Cells (immunology, pathology)
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: